谢春梅,沈梦奇,朱达,王首正,骆志玲,潘湘斌

• 1:云南省阜外心血管病医院昆明医科大学附属心血管医院麻醉科
• 2:云南省阜外心血管病医院昆明医科大学附属心血管医院结构性心脏病中心
• 3:国家心血管病中心北京协和医学院中国医学科学院阜外医院结构性心脏病中心
• 4:云南省阜外心血管病医院昆明医科大学附属心血管医院超声科

摘要(Abstract)：

三尖瓣反流（TR）是常见的心脏瓣膜病变。根据发病机制，TR可分为原发性（器质性）和继发性（功能性）反流，其中功能性TR占比超过90%。重度TR患者预后差，药物治疗效果差，外科手术（瓣环成形）是主要治疗手段。目前，经导管三尖瓣缘对缘修复术（T-TEER）已成为TR经导管治疗的重要方案，为广大无法接受外科手术或手术高风险的TR患者提供了微创治疗方式。T-TEER通过夹闭瓣叶进而降低反流程度，目前处于早期研发探索和临床验证阶段，主要用于功能性TR。T-TEER相关器械也取得了明显的进步（TriClip,PASCAL），我国独立研发的T-TEER器械也正在进行临床试验（DragonFly-T~(TM),SQ-Kyrin-T~(TM),NeoBlazar~(TM)）。本文对T-TEER的应用现状和研究进展进行综述。

关键词(KeyWords)： 三尖瓣反流;经导管三尖瓣缘对缘修复术;介入治疗

Abstract:

Keywords:

基金项目(Foundation): “十四五”重点研发计划项目（2022YFC2503400）;; 云南省心血管系统疾病临床医学研究中心-重大心血管疾病诊治新技术研发项目（202102AA310002）;; 云南省重大科技专项计划项目（202302AA310045）

作者(Author): 谢春梅,沈梦奇,朱达,王首正,骆志玲,潘湘斌

参考文献(References)：

• [1]Topilsky Y,Maltais S,Medina Inojosa J,et al.Burden of tricuspid regurgitation in patients diagnosed in the community setting[J].JACC Cardiovasc Imaging,2019,12(3):433-442.DOI:10.1016/j.jcmg.2018.06.014.
• [2]Yang L,Chen H,Pan W,et al.Analyses for prevalence and outcome of tricuspid regurgitation in China:an echocardiography study of134,874 patients[J].Cardiology,2019,142(1):40-46.DOI:10.1159/000496601.
• [3]Rogers JH,Bolling SF.The tricuspid valve:current pers p ectiv e and evolving management of tricuspid regurgitation[J].Circulation,2009,119(20):2718-2725.DOI:10.1161/CIRCULATIONAHA.108.842773.
• [4]Badano LP,Muraru D,Enriquez-Sarano M. Assessment of functional tricuspid regurgitation[J].Eur Heart J,2013,34(25):1875-1885.DOI:10.1093/eurheartj/ehs474.
• [5]Otto CM,Nishimura RA,Bonow RO,et al.2020 ACC/AHA Guideline for the management of patients with valvular heart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J].Circulation,2021,143(5):e35-e71.DOI:10.1161/CIR.0000000000000932.
• [6]Stuge O,Liddicoat J.Emerging opportunities for cardiac surgeons within structural heart disease[J].J Thorac Cardiovasc Surg,2006,132(6):1258-1261.DOI:10.1016/j.jtcvs.2006.08.049.
• [7]Vassileva CM,Shabosky J,Boley T,et al.Tricuspid valve surgery:the past 10 years from the Nationwide Inpatient Sample(NIS)database[J].J Thorac Cardiovasc Surg,2012,143(5):1043-1049.DOI:10.1016/j.jtcvs.2011.07.004.
• [8]Bernal JM,Morales D,Revuelta C,et al.Reoperations after tricuspid valve repair[J].J Thorac Cardiovasc Surg,2005,130(2):498-503.DOI:10.1016/j.jtcvs.2004.12.044.
• [9]Vanian A,Beversdorf F,Praz F,et al.2021 ESC/EACTS Guidelines for management of valvular heart diseases[J].Eur Heart J,2022,43(7):561-632.DOI:10.1093/eurbeani/ehab395.
• [10]马翔,王宝珠,马依彤.2022年度全球瓣膜病领域大事件盘点[J].中国介入心脏病学杂志,2023,31(1):19-24.DOI:10.3969/j.issn.1004-8812.2023.01.004.
• [11]刘先宝,任凯达,蒲朝霞,等.经导管三尖瓣缘对缘修复术操作流程[J].中国介入心脏病学杂志,2023,31(5):387-393.DOI:10.3969/j.issn.1004-8812.2023.05.011.
• [12]Kowalski M,Franz N,Ritter F,et al.Simultaneous transfemoral transcatheter mitral and tricuspid valve edge-to-edge repair(using MitraClip system)completed by atrial septal defect occlusion in a surgically inoperable patient.First-in-human report[J].Kardiochir Torakochirurgia Pol,2015,12(4):295-297.DOI:10.5114/kitp.2015.56776.
• [13]Taramasso M,Hahn RT,Alessandrini H,et al.The international multicenter TriValve registry:which patients are undergoing transcatheter tricuspid repair?[J].JACC Cardiovasc Interv,2017,10(19):1982-1990.DOI:10.1016/j.jcin.2017.08.011.
• [14]Mehr M,Taramasso M,Besler C,et al.1-year outcomes after edgeto-edge valve repair for symptomatic tricuspid regurgitation:results from the TriValve registry[J].JACC Cardiovasc Interv,2019,12(15):1451-1461.DOI:10.1016/j.jcin.2019.04.019.
• [15]Zoghbi WA,Adams D,Bonow RO,et al.Recommendations for noninvasive evaluation of native valvular regurgitation:a report from the American Society of Echocardiography Developedin Collaboration with the Society for Cardiovascular Magnetic Resonance[J].J Am Soc Echocardiogr,2017,30(4):303-371.DOI:10.1016/j.echo.2017.01.007.
• [16]Besler C,Orban M,Rommel KP,et al.Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair[J].JACC Cardiovasc Interv,2018,11(12):1119-1128.DOI:10.1016/j.jcin.2018.05.002.
• [17]Lurz P,Stephan von Bardeleben R,Weber M,et al.Transcatheter edge-to-edge repair for treatment of tricuspid regurgitation[J].J Am Coll Cardiol,2021,77(3):229-239.DOI:10.1016/j.jacc.2020.11.038.
• [18]von Bardeleben RS,Lurz P,Sorajja P,et al.Twoyear outcomes for tricuspid repair with a transcatheter edgeto-edge valve repair from the transatlantic TRILUMINATE trial[J].Circ Cardiovasc Interv,2023,16(8):e012888.DOI:10.1161/CIRCINTERVENTIONS.122.012888.
• [19]Sorajja P,Whisenant B,Hamid N,et al.Transcatheter repair for patients with tricuspid regurgitation[J].N Engl J Med,2023,388(20):1833-1842.DOI:10.1056/NEJMoa2300525.
• [20]Adams DH.TRILUMINATE pivotal:outcomes of all randomized and the single-arm subjects with transcatheter tricuspid valye edgeto-edge repair for tricuspid regurgitation[EB/OL].(2023-10-24)[2023-12-01].https://www.drvoice.cn/v2/article/12274.
• [21]潘文志,龙愉良,周达新,等.经导管缘对缘修复:定义、分类及技术更新[J].中国介入心脏病学杂志,2022,30(6):440-444.DOI:10.3969/j.issn.1004-8812.2022.06.009.
• [22]Kodali SK,Hahn RT,Davidson CJ,et al.1-year outcomes of transcatheter tricuspid valve repair[J].J Am Coll Cardiol,2023,81(18):1766-1776.DOI:10.1016/j.jacc.2023.02.049.
• [23]Wild MG,L?w K,Rosch S,et al.Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation[J].JACC Cardiovasc Interv,2022,15(13):1352-1363.DOI:10.1016/j.jcin.2022.05.041.
• [24]台适,刘家乐,方臻飞.经导管三尖瓣反流缘对缘修复术治疗进展[J].华西医学,2021,36(9):1250-1254.DOI:10.7507/1002-0179.202107258.
• [25]王建安,刘先宝,蒲朝霞,等.经导管三尖瓣缘对缘修复术1例及其2年随访结果[J].中华心血管病杂志,2023,51(6):662-664.DOI:10.3760/cma.j.cn112148-20230304-00120.
• [26]潘湘斌.EuroPCR 2023|中国创新器械SQ-Kyrin-T~(TM)经导管三尖瓣夹FIM研究结果亮相国际舞台[EB/OL].(2023-05-19)2023-12-01].https://www.drvoice.cn/v2/article/11233.